Meridian Assay

Independent analytical testing - Cambridge MA

TASK NO.
6R2M8WX
Report MA-ARA-0041 - Rev. 01

CERTIFICATE OF ANALYSIS

ARA290 - 10 mg


Cibinetide - synthetic 11-residue peptide - sequence pGlu-EQLERALNSS - lyophilised

Material	ARA290	Client	novumpeptides.com	Received	2026-09-15 at 2-8 C
Batch / lot	ARA-41-8WX	Label claim	10 mg	Analysed	2026-09-16 to 2026-09-17

TEST RESULTS

ATTRIBUTE	RESULT	SPECIFICATION	METHOD	VERDICT
Identity	**Conforms**	Matches reference	MA-MS-014 / LC-HRMS	Conforms
Purity (area %)	**99.57%**	>= 99.00%	MA-UHPLC-031 / UV 214	Pass
Largest single impurity	**0.13%**	<= 0.50%	MA-UHPLC-031 / UV 214	Pass
Total related substances	**0.43%**	<= 1.00%	MA-UHPLC-031 / UV 214	Pass
ARA290 per vial	**10.03 mg**	9.00-11.00 mg	MA-ASSAY-011 / UHPLC-UV	Pass
Water content	**4.12%**	<= 8.00%	MA-KF-004 / Karl Fischer	Pass
Residual acetonitrile	**121 ppm**	<= 410 ppm	MA-GC-006 / HS-GC-FID	Pass
Residual TFA	**0.18%**	<= 1.00%	MA-IC-003 / ion chromatography	Pass

RP-UHPLC processed trace, UV detection



Record 6R2M8WX-PEP-01; duplicate independent preparations. System suitability met retention-time and resolution criteria; blank response was below threshold.

Related species profile

Related peak A	0.13%
Related peak B	0.10%
Related peak C	0.07%
Related peak D	0.05%
Related peak E	0.04%
Related peak F	0.04%

Related species reported by integrated UV peak area. Structural assignments are not made. Reporting threshold: 0.03% area.

Conclusion

Identity and quality attributes met the stated criteria. Mean ARA290 content was 10.03 mg/vial and chromatographic purity was 99.57%.

Identity was established by LC-HRMS against a qualified reference; content and related substances were assessed independently.

Analytical review
Ines Abadi I.Abadi

Quality review
Marcus Oyelaran
Prepared: 2026-09-18 M.Oyelaran

Decision rule: simple acceptance; reported results are compared directly with the stated project specifications.